| Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. | |
| | |
MedLine Citation:
|
PMID: 20102310 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Mifepristone is a synthetic selective progesterone-receptor modulator (SPRM) that is widely used around the globe in the field of reproductive medicine. At present mifepristone is approved in a number of countries for early termination of pregnancy (TOP), cervical dilatation before surgical TOP, and management of early embryonic loss or fetal death. A number of new clinical applications are being developed in gynecology, endocrinology and oncology. Mifepristone has also served as an invaluable tool in the study of steroid hormone biology. AREAS COVERED IN THIS REVIEW: Current indications for mifepristone are reviewed. New applications for mifepristone under clinical investigation are discussed. In addition, the unique molecular and cellular effects of mifepristone are described. WHAT THE READER WILL GAIN: The reader will understand the mechanisms of action of mifepristone and the underlying steroid hormone biology. The reader will know the approved clinical indications for mifepristone and appreciate the ongoing basic and clinical research into new applications. TAKE HOME MESSAGE: Mifepristone is the first-discovered and still most widely used antiprogestin. It has several indications in reproductive medicine and is under investigation for a variety of potential applications in other fields of medicine. The molecular and cellular effects of mifepristone illuminate important aspects of steroid hormone biology. |
| | |
Authors:
|
Annie Im; Leonard J Appleman |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 11 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-27 Completed Date: 2010-04-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 481-8 Citation Subset: IM |
Affiliation:
|
University of Pittsburgh, Division of Hematology/Oncology, Department of Medicine, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abortifacient Agents, Steroidal
/
administration & dosage,
pharmacology*,
therapeutic use Drug Approval / legislation & jurisprudence Drug Delivery Systems Drug Design* Endocrinology / classification Female Humans Medical Oncology / classification Mifepristone / administration & dosage, pharmacology*, therapeutic use Pregnancy Pregnancy Complications, Neoplastic / drug therapy, prevention & control Reproductive Medicine / classification Uterine Neoplasms / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Abortifacient Agents, Steroidal; 84371-65-3/Mifepristone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ciclesonide and the treatment of asthma.
Next Document: Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation.